CompletedNot Applicable

Endothelial Dysfunction as a Predictive Marker of Acute Graft-Versus-Host Disease in Adult Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Italy50 participantsStarted 2021-06-04

Plain-language summary

Assess whether the CEC count in peripheral blood, analyzed at baseline T0, can predict the risk of acute GvHD onset.

Who can participate

Age range18 Years – 70 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Aged between 18 and 70 years old * First allogeneic hematopoietic stem cell (HSC) transplant for hematological disease * Use of HSCs from bone marrow, peripheral blood, or cord blood * Use of HLA-identical related donors, haploidentical related donors, HLA-identical registry donors, registry donors with mismatches at major HLA loci * Signing of informed consent Exclusion Criteria: * Age \< 18 years or \>70 years * Patients receiving allogeneic HSC transplantation for non-hematologic disease * Second or subsequent allogeneic HSC transplantation

What they're measuring

Predict the risk of aGvHD onset.

Timeframe: During the 18-month enrollment period, approximately 50 adult patients receiving HSCT are expected to be enrolled.

Trial details

NCT IDNCT07508345

SponsorFondazione IRCCS Policlinico San Matteo di Pavia

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2022-07-31

View on ClinicalTrials.gov More GVHD trials